Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease

NCT07123350 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Inflammatory Bowel Disease (IBD)
Crohn&Amp;#39;s Disease (CD)
Ulcerative Colitis (UC)

Interventions

DRUG: Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care

Sponsor

Vanderbilt University Medical Center

Collaborators

[object Object]